Literature DB >> 11431761

Surfactant and inhaled nitric oxide in rats alleviate acute lung injury induced by intestinal ischemia and reperfusion.

S Zheng1, W Y Zhang, L W Zhu, K Lin, B Sun.   

Abstract

BACKGROUND: Respiratory distress and acute lung injury (ALI) are severe complications of intestinal ischemia and reperfusion injury (I/R). The authors hypothesize that a combined surfactant and inhaled nitric oxide (iNO) may alleviate I/R-induced ALI.
METHODS: Adult rats (body weight 285 to 315 g, n = 45) were allocated randomly to either a negative control group (N-Control, n = 9) with only sham laparotomy, or groups (n = 9 each) for induction of I/R by occlusion of superior mesenteric artery, followed by treatment with (1) surfactant at 100 mg/kg (Surf), (2) iNO at 20 ppm (NO), (3) both surfactant and iNO (SNO), or (4) no surfactant no iNO (a positive control, P-Control). Mechanical ventilation was provided for 120 minutes with variable peak insufflation pressure and FIO2 to achieve adequate arterial pH, PaO2, and PaCO2. Blood gas values, dynamic lung compliance (Cdyn), and airway resistance (Raw) were measured during the 2-hour treatment. Lung wet-to-dry weight ratio (W/D), histopathology, and morphometric analysis of alveolar expansion (V(V)) were determined at the end of the experiment.
RESULTS: After 120 minutes of treatment, the SNO group had the highest PaO2 and Cdyn values, close to that of the N-Control group. The Surf, NO, and SNO groups had higher V(V) and lower CV (V(V)) values than the P-Control, but modest decrease of W/D values. The NO group had moderately improved PaO2 but Cdyn and V(V) were as low as that of the P-Control. The lungs of the SNO group had significantly alleviated edema and neutrophil infiltration compared with the P-Control.
CONCLUSIONS: The combined surfactant and iNO treatment alleviated rat ALI induced by I/R, and exerted effects better than the use of surfactant or iNO alone. Copyright 2001 by W.B. Saunders Company.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11431761     DOI: 10.1053/jpsu.2001.24721

Source DB:  PubMed          Journal:  J Pediatr Surg        ISSN: 0022-3468            Impact factor:   2.545


  7 in total

1.  Mixed serum-deprived and normal adipose-derived mesenchymal stem cells against acute lung ischemia-reperfusion injury in rats.

Authors:  Cheuk-Kwan Sun; Steve Leu; Shu-Yuan Hsu; Yen-Yi Zhen; Li-Teh Chang; Ching-Yen Tsai; Yung-Lung Chen; Yen-Ta Chen; Tzu-Hsien Tsai; Fan-Yen Lee; Jiunn-Jye Sheu; Hsueh-Wen Chang; Hon-Kan Yip
Journal:  Am J Transl Res       Date:  2015-02-15       Impact factor: 4.060

2.  Pycnogenol, a compound isolated from the bark of pinus maritime mill, attenuates ventilator-induced lung injury through inhibiting NF-κB-mediated inflammatory response.

Authors:  Y F Xia; J H Zhang; Z F Xu; X M Deng
Journal:  Int J Clin Exp Med       Date:  2015-02-15

Review 3.  Extrapulmonary effects of inhaled nitric oxide: role of reversible S-nitrosylation of erythrocytic hemoglobin.

Authors:  Timothy J McMahon; Allan Doctor
Journal:  Proc Am Thorac Soc       Date:  2006-04

Review 4.  Surfactant therapy for acute lung injury and acute respiratory distress syndrome.

Authors:  Krishnan Raghavendran; D Willson; R H Notter
Journal:  Crit Care Clin       Date:  2011-07       Impact factor: 3.598

Review 5.  Pharmacotherapy of acute lung injury and acute respiratory distress syndrome.

Authors:  Krishnan Raghavendran; Gloria S Pryhuber; Patricia R Chess; Bruce A Davidson; Paul R Knight; Robert H Notter
Journal:  Curr Med Chem       Date:  2008       Impact factor: 4.530

6.  Oroxylin-A rescues LPS-induced acute lung injury via regulation of NF-κB signaling pathway in rodents.

Authors:  Tzu-Ling Tseng; Mei-Fang Chen; Ming-Jen Tsai; Yung-Hsiang Hsu; Chin-Piao Chen; Tony J F Lee
Journal:  PLoS One       Date:  2012-10-10       Impact factor: 3.240

7.  ATF3 Protects against LPS-Induced Inflammation in Mice via Inhibiting HMGB1 Expression.

Authors:  Pei-Fang Lai; Ching-Feng Cheng; Heng Lin; Tzu-Ling Tseng; Hsi-Hsien Chen; Sung-Ho Chen
Journal:  Evid Based Complement Alternat Med       Date:  2013-08-26       Impact factor: 2.629

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.